Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1006
mi
from 43215
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Bismarck Cancer Center
1006
mi
from 43215
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1006
mi
from 43215
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Medcenter One Hospital Cancer Care Center
1006
mi
from 43215
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1006
mi
from 43215
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Mid Dakota Clinic, PC
1006
mi
from 43215
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1003
mi
from 43215
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Alexius Medical Center Cancer Center
1003
mi
from 43215
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
885
mi
from 43215
Grand Forks, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Altru Cancer Center at Altru Hospital
885
mi
from 43215
Grand Forks, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
344
mi
from 43215
Danville, PA
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Geisinger Cancer Institute at Geisinger Health
344
mi
from 43215
Danville, PA
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
385
mi
from 43215
Wilkes-Barre, PA
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
385
mi
from 43215
Wilkes-Barre, PA
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1071
mi
from 43215
Rapid City, SD
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rapid City Regional Hospital
1071
mi
from 43215
Rapid City, SD
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
403
mi
from 43215
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
403
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
407
mi
from 43215
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Mary's Hospital
407
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
407
mi
from 43215
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Mary's Hospital Medical Center - Green Bay
407
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
403
mi
from 43215
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Vincent Hospital Regional Cancer Center
403
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
497
mi
from 43215
La Crosse, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Franciscan Skemp Healthcare - La Crosse Campus
497
mi
from 43215
La Crosse, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
371
mi
from 43215
Manitowoc, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Holy Family Memorial Medical Center Cancer Care Center
371
mi
from 43215
Manitowoc, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
425
mi
from 43215
Marinette, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Bay Area Cancer Care Center at Bay Area Medical Center
425
mi
from 43215
Marinette, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
403
mi
from 43215
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Door County Cancer Center at Door County Memorial Hospital
403
mi
from 43215
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
405
mi
from 43215
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited - Sturgeon Bay
405
mi
from 43215
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1217
mi
from 43215
Casper, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rocky Mountain Oncology
1217
mi
from 43215
Casper, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
1261
mi
from 43215
Sheridan, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Welch Cancer Center at Sheridan Memorial Hospital
1261
mi
from 43215
Sheridan, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
232
mi
from 43215
Saint Joseph, MI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Lakeland Regional Cancer Care Center - St. Joseph
232
mi
from 43215
Saint Joseph, MI
Click here to add this to my saved trials
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
Phase I Assessment of NO Mediated Signaling in Cancer Cachexia
Status: Enrolling
Updated:  10/25/2017
992
mi
from 43215
Galveston, TX
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
Phase I Assessment of NO Mediated Signaling in Cancer Cachexia
Status: Enrolling
Updated: 10/25/2017
University of Texas Medical Branch
992
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/25/2017
4499
mi
from 43215
Honolulu, HI
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/25/2017
Univ of Hawaii
4499
mi
from 43215
Honolulu, HI
Click here to add this to my saved trials
11C-acetate for Treatment Response After Radiotherapy for HCC
Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  10/25/2017
167
mi
from 43215
Indianapolis, IN
11C-acetate for Treatment Response After Radiotherapy for HCC
Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 10/25/2017
Indiana University
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
RCT of Strategies to Improve Screening Rates Among a Cohort of Cirrhotic Patients at High Risk for Developing HCC in a Safety-net Health System
Status: Enrolling
Updated:  11/2/2017
911
mi
from 43215
Dallas, TX
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
RCT of Strategies to Improve Screening Rates Among a Cohort of Cirrhotic Patients at High Risk for Developing HCC in a Safety-net Health System
Status: Enrolling
Updated: 11/2/2017
Parkland Health and Hospital System
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard
Status: Enrolling
Updated:  11/13/2017
442
mi
from 43215
Princeton, NJ
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard
Status: Enrolling
Updated: 11/13/2017
Bracco Diagnostics Inc.
442
mi
from 43215
Princeton, NJ
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
1343
mi
from 43215
Billings, MT
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Billings Clinic
1343
mi
from 43215
Billings, MT
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
823
mi
from 43215
Tampa, FL
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
563
mi
from 43215
Rochester, MN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mayo Clinic Cancer Clinical Studies Unit
563
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
476
mi
from 43215
Hackensack, NJ
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Hackensack University Medical Center
476
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
478
mi
from 43215
New York, NY
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
NYU Cancer Institute - Bellevue Hospital
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
332
mi
from 43215
Nashville, TN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Sarah Cannon Research Institute Drug Development Unit
332
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
911
mi
from 43215
Dallas, TX
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mary Crowley Medical Research Center
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
499
mi
from 43215
Toulouse Cedex,
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Institut Claudius Regaud
499
mi
from 43215
Toulouse Cedex,
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
1972
mi
from 43215
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
1972
mi
from 43215
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
UCLA Neuro-Oncology Program
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
2108
mi
from 43215
San Francisco, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  11/13/2017
2108
mi
from 43215
San Francisco, CA
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  11/13/2017
7988
mi
from 43215
Hong Kong,
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
7988
mi
from 43215
Hong Kong,
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer
Status: Enrolling
Updated:  11/19/2017
996
mi
from 43215
Houston, TX
Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer
Status: Enrolling
Updated: 11/19/2017
Burzynski Clinic
996
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated:  11/27/2017
624
mi
from 43215
Minneapolis, MN
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary
Status: Enrolling
Updated:  11/29/2017
624
mi
from 43215
Minneapolis, MN
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary
Status: Enrolling
Updated: 11/29/2017
Edward W. Greeno, MD
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Status: Enrolling
Updated:  11/29/2017
1645
mi
from 43215
Scottsdale, AZ
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Status: Enrolling
Updated: 11/29/2017
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated:  12/3/2017
624
mi
from 43215
Minneapolis, MN
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer
Status: Enrolling
Updated:  12/3/2017
992
mi
from 43215
Miami, FL
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer
Status: Enrolling
Updated: 12/3/2017
University of Miami
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated:  12/3/2017
624
mi
from 43215
Minneapolis, MN
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
274
mi
from 43215
Chicago, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
314
mi
from 43215
Decatur, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Decatur Memorial Hospital
314
mi
from 43215
Decatur, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
267
mi
from 43215
Harvey, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Ingalls Memorial Hospital
267
mi
from 43215
Harvey, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
137
mi
from 43215
Fort Wayne, IN
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Fort Wayne Medical Oncology and Hematology
137
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
164
mi
from 43215
Ann Arbor, MI
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
University of Michigan Comprehensive Cancer Center
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials